Physician profile
Amitasha Mann
NPI 1619215837
$2,695.83
in general payments reported to CMS, 2019-2025
32 companies · $616 in 2025
The $616 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $161 · 2021: $379 · 2022: $207 · 2023: $314 · 2024: $557 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,487.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $578.52 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $289.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $236.84 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $222.79 | 2021-2025 | |
| Glaxosmithkline, LLC. | $202.58 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $178.85 | 2019-2025 | |
| Amgen INC. | $170.31 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbott Laboratories | $110.58 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $91.06 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.60 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $60.52 | 2021 | |
| Novartis Pharmaceuticals Corporation | $39.79 | 2020-2022 | |
| Eisai INC. | $36.55 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $34.84 | 2020-2021 | |
| Astellas Pharma US INC | $29.16 | 2024 | Veozah |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $27.43 | 2025 | Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $27.42 | 2025 | Trintellix |
| Mannkind Corporation | $25.92 | 2019 | |
| Arbor Pharmaceuticals, INC. | $25.80 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $25.59 | 2023 | Evkeeza |
| Esperion Therapeutics, INC. | $23.39 | 2023 | Nexletol |
| Exact Sciences Corporation | $22.92 | 2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $22.35 | 2019 | |
| Verity Pharmaceuticals INC. | $21.31 | 2024 | Tlando |
| Phathom Pharmaceuticals, INC. | $20.68 | 2025 | Voquezna |
| Dynavax Technologies Corporation | $18.12 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $17.72 | 2022 | |
| Merck Sharp & Dohme LLC | $16.95 | 2019 | |
| Dexcom, INC. | $16.83 | 2024 | Dexcom G6 Transmitter |
| Tolmar, INC. | $15.25 | 2025 | Jatenzo |
| Medtronic USA, INC. | $12.91 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amitasha Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.